Granahan Investment Management LLC Has $9.60 Million Stake in Xeris Biopharma Holdings, Inc. $XERS

Granahan Investment Management LLC grew its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 249.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,223,404 shares of the company’s stock after buying an additional 873,236 shares during the period. Granahan Investment Management LLC’s holdings in Xeris Biopharma were worth $9,604,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of XERS. Royal Bank of Canada grew its position in Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after purchasing an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Xeris Biopharma by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares during the last quarter. Millennium Management LLC grew its position in Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP acquired a new stake in Xeris Biopharma in the 1st quarter worth $170,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director John Johnson sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $91,350.00. Following the sale, the director directly owned 683,083 shares in the company, valued at approximately $4,159,975.47. This represents a 2.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Marla Persky sold 15,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $5.90, for a total value of $91,450.00. Following the completion of the sale, the director owned 126,500 shares in the company, valued at approximately $746,350. This represents a 10.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 127,335 shares of company stock worth $766,733. Insiders own 4.35% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $10.80.

Xeris Biopharma Trading Up 0.3%

XERS stock opened at $6.90 on Wednesday. Xeris Biopharma Holdings, Inc. has a 1-year low of $4.40 and a 1-year high of $10.08. The firm has a market cap of $1.19 billion, a P/E ratio of 115.00 and a beta of 0.78. The business’s 50 day moving average is $6.23 and its 200-day moving average is $6.57. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The company had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.